In this paper, we aim to focus on false positive results in the evaluation of thyroid aspirations, covering cystic, inflammatory, follicular and oncocytic lesions, papillary carcinoma, and medullary carcinoma of thyroid. The recently described entity, "noninvasive follicular thyroid neoplasm with papillary-like nuclear features" (NIFTP), is also discussed detailing the impact of its introduction on the sensitivity and specificity of thyroid FNA, as well as the use of molecular tests for diagnostics. Medicolegal issues in relation to current practice in English law are also described.
Introduction
Fine-needle aspiration cytology (FNAC) is widely accepted as a rapid, cost-effective, and safe method for the diagnosis of thyroid nodules although it is accepted that false positive diagnoses of malignancy do occur. 1, 2 The positive predictive value of FNAC for malignancy according to The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) is 97%-99%, and this figure includes NIFTP tumours, the sensitivity and specificity of thyroid FNAC have been reported as 65%-99% and 72%-100%, respectively. and Thy 4 (equivalent to Bethesda Category V) 74.4% (623 / 837 cases) 6 .
The main goal of thyroid FNAC is to determine the presence or absence of a neoplasm, then to diagnose any neoplasm present as benign or malignant, and finally to determine the exact type of tumour present. 2, 4, 7 Thyroid FNAC can be used as a 'rule in' test most of the time for papillary carcinoma but for follicular and medullary carcinomas for example, thyroid cytology functions as a 'rule out' test much of the time. In adults, FNA has been established in large reviews as a useful test in the differentiation of a thyroid nodule as malignant or benign. 8, 9 Many research groups have found that FNA in children and adolescents is a highly sensitive and accurate test in differentiating benign from malignant nodules. 10 -13 In a study 4 by Stevens et al, sensitivity and specificity of this test in the pediatric population were 94%
(95% confidence interval [CI] , 86%-100%) and 81% (95% CI, 72%-91%). 14 However, misdiagnosis of cancer by cytopathology examination has remained one of the most problematic issues in thyroid pathology. The rate of false-positive FNAC for thyroid nodules has been reported as 2%-10%, 3 ,15 compared with rates of 0%-14% for false-negative results 16, 17 . The mean risk of malignancy for lesions classified as suspicious for malignancy and malignant in TBSRTC is 75.2% and 98.6%, respectively. Overdiagnosis resulting from cytopathology results may lead to excessive treatment, specifically, unnecessary thyroidectomy and also other treatments. Considering the current trend towards conservative treatment for patients with thyroid carcinoma, false positivity can be as problematic as false negativity. In particular, thyroid surgeons could face the experience of performing unnecessary surgery in patients with false positive results. 3 In this paper, we discuss the main causes of false positive in thyroid FNAC (Table 1) . We divided the lesions in two groups:
cystic and solid.
Cystic Lesions
The term cystic thyroid nodule is used to describe any fluid-filled thyroid nodule.
Approximately 15% to 25% of solitary thyroid nodules are cystic or predominantly cystic, and most nodules are benign. 18 Despite the good performance of FNAC in the evaluation of thyroid nodules, its accuracy is lower in cystic lesions than in solid masses . [19] [20] [21] Cystic changes and degenerative processes may cause florid atypia which is a significant cause of false positive and negative results. In a study on thyroid cysts containing atypical cells, among 12 selected cytological features, intranuclear pseudoinclusions, papillary microarchitecture, nuclear crowding and mitoses were the ones suggesting carcinoma.
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Because of some studies suggesting that atypical cells can be the cause of false positive repeat FNA over a short period of time, the previous edition of TBSRTC suggested to wait at least 3 months before repeating the FNA, however, the 2017 edition of TBSRTC did not accept the evidence for the effect of early repeat FNA on increased atypical results 2 . Histological alterations can occur following thyroid FNAC, such as infarction, necrosis and vascular changes. These alterations are not frequent but can cause false-positive histological diagnosis. Thin needles and a non-aspiration FNAC technique can reduce these findings. 23 Squamous metaplasia can be also a source of a false-positive diagnosis. Cystic lesions of congenital rest origin, such as intrathyroidal lymphoepithelial cysts of probable branchial cleft origin are often sources of intrathyroidal squamous cells. The FNA specimens from these cysts consist of macrophages, neutrophils, and a mucoid or proteinaceous background admixed with squamous cells. 24 In some cases, the squamous metaplasia can be so extensive that may lead to the suspicion of PTC with squamous differentiation. 24 If atypical cytologic features are appreciated in a smear with a mixed pattern (few squamous cells, follicular cells and colloid, plus/minus inflammatory cells and macrophages), reactive squamous metaplasia arising in the background of cystic change or Hashimoto thyroiditis is the most likely explanation. 24 In some situations, performing a cell block in a cystic aspirate can convert nondiagnostic results into a satisfactory sample, as well avoiding false-positive results.
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Inflammatory Lesions
Inflammatory lesions of thyroid include acute, granulomatous thyroiditis and lymphocytic thyroiditis (Hashimoto's thyroiditis). FNA is indicated in these situations when by palpation or imaging a nodule is identified. (Figure 2 ). Cell debris in the background of smears can also simulate necrosis (Figure 3 ). Recognizing the cytomorphological details of multinucleated giant cells, epithelioid histiocytes, and fibrotic degenerate stromal fragments in the busy background created by acute-chronic inflammation and debris is important to prevent false positive diagnosis in this entity.
Acute suppurative thyroiditis
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Lymphocytic Thyroiditis/Grave´s Disease
Hashimoto's thyroiditis is a well-established entity with typical clinical and cytomorphological findings. In the initial phase, there is antibody-mediated destruction of 8 thyroid follicles and lymphocytic infiltration. In the chronic phase, there will often be only minimal residual and atrophic follicles with fibrosis of the thyroid parenchyma. Graves' disease is a common cause of hyperthyroidism and reported rates of malignancy vary between 2.3-19%. 4 Oncocytic and/or non-oncocytic thyroid follicular epithelial cells,large amounts of flame cells, watery colloid, lymphocytes, and rarely granulomas are seen in aspirations. 33 Cytological findings are challenging, especially after treatment. 34 Distinctive pleomorphism, hyperchromasia, elongation of nuclei with occasional grooves and inclusions can be seen in this entity. 4, 33, 34 To diagnose PTC in the background of Graves´ disease, all the PTC criteria should be present in the aspirates. 
Follicular-pattern Lesions
The main diagnostic challenge of FNA is what to do with the finding of follicular cells on FNA cytology. 35 The range of follicular lesions of the thyroid includes adenomatoid Microfollicles are composed of less than 15 overlapping thyroid follicular epithelial cells forming a circle that is at least two-thirds complete with or without intraluminal dense colloid. 37 Macrofollicles, form small or large flat sheets/groups or even rows but not circles;
overlapping is not their character. Microfollicles can be observed as primary pattern-scattered isolated single microfollicles-or in groups as secondary pattern. In bloody smears, the presence of clots can create pseudo microfollicular appearance and we should be careful not to call the crowded small groups in clot microfollicles ( Figure 6 ). In this situation, observing microfollicles out of the clot may be helpful. Recently a subset of encapsulated FV-PTC with a very indolent clinical course was defined when treated with lobectomy alone (without radioactive iodine treatment). This new entity was called "noninvasive follicular thyroid neoplasm with papillary-like nuclear features" (NIFTP) and there are specific criteria for this diagnosis. 38 Since this lesion is considered "a very low risk malignancy" but it shares some cytological findings with PTC, it should also be considered a potential cause of false positive results in thyroid FNA. 39 The challenge posed by NIFTP is especially with the "suspicious for malignancy" and "malignant" categories, where the FNA diagnosis can frequently prompt initial total thyroidectomy, but where more conservative management (i.e. lobectomy) would be preferable if the histological diagnosis proves to be NIFTP. 38 The effects of reclassification of some cases of FV-PTC as NIFTP on the risk of malignancy (ROM) associated with the categories of TBSRTC are minimal if strict criteria are used. 39, 40, 41 To avoid false positive FNAC, the six criteria for PTC recommended by TBSRTC are required for a definitive diagnosis of malignancy: enlarged nuclei, oval or irregularly shaped and sometimes moulded nuclei, longitudinal nuclear grooves, intranuclear cytoplasmic pseudoinclusions, pale nuclei with powdery chromatin, and marginally placed micronucleoli.
2,41 A recent study involving approximately 500 cases showed that the presence of 3 or more intranuclear pseudoinclusions is one of the best criteria to discriminate PTC from lesions classified as suspicious at cytology. 41 Samples from FVPTC's demonstrate a microfollicular 14 growth pattern with varying degrees of nuclear alterations (nuclear enlargement, membrane irregularities, and chromatin clearing). If the latter nuclear alterations associated with FVPTC are abundantly present in cytology samples, an accurate presurgical diagnosis of PTC may be rendered. Conversely, when these nuclear alterations are found in few cells, the specificity for malignancy also decreases because these alterations are observed in benign reactive conditions. In the explanatory notes on FVPTC, the TBSRTC states "current practice suggests that only the cases with definitive nuclear features of PTC should be diagnosed unequivocally on FNA". 2 Because the threshold for making a cytopathological diagnosis of malignancy lies in the balance between the sensitivity to diagnose low-grade PTCs such as FVPTC and the specificity to minimize the risk of a false-positive diagnosis, the focus has shifted toward the interpretation of "definitive nuclear features".
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Molecular correlation is also indicated since in many studies the NIFTP group of lesions show "RAS-like" mutations and BRAF V600E mutations are almost non existent when the criteria for NIFTP are strictly applied 41 . (See further discussion in the molecular section).
Papillary thyroid carcinoma
Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy. The pathological diagnosis and classification of PTC is usually based on the microscopic appearance of biopsy specimens. Misdiagnosis of PTC by cytopathological methods has remained one of the most problematic issues in pathology. 3 The pitfalls related to the cytological diagnosis of PTC should be analyzed in two parts concerning pattern and nuclear features. It is well known that nuclear details are the core of PTC diagnosis: "enlargement, oval shape, membrane irregularity, clearing, longitudinal grooves, intranuclear pseudoinclusions. Among the nuclear features of PTC, the most specific is intranuclear pseudoinclusions. 41 One should be strict to define intranuclear pseudoinclusions, since their 15 presence makes the aspirate at least suspicious for PTC. Intranuclear pseudoinclusions should be large enough and well-delineated with darker outlines to be discriminated from superimposed erythrocytes and artefacts. Nuclear grooves are usually present in PTCs, but to be reliable enough they should be widespread and clear rather than being a focal change or an artificial appearance caused by overlapping cells. Hypochromasia/nuclear clearing is an alerting finding, however depending on technical issues it might be misleading on its own.
Uniformly enlarged oval shaped nuclei are also important in the diagnosis. 1, 3, 4 The patterns of cytologic atypia mimicking PTC, formation of papillae or caps, are described in the literature. 1, 4 Pseudopapillary formation as an architectural pitfall is well document by Majahan et al. 48 This study also stated that the presence of intranuclear cytoplasmic pseudoinclusions in parathyroid adenomas, not only overlaps with FN, but can also mimic PTC on aspirates.
Psammoma bodies are quite specific for PTC; however dystrophic calcifications and dense colloid bodies should not be interpreted as psammoma bodies as these are almost never laminated in appearance in contrast to psammoma bodies. Another point is the amount and type of colloid that is usually scanty and of bubble-gum type in PTC. However, stromal degenerative fragments can mimic bubble-gum type colloid and large amounts of loose colloid may also be seen in PTC. Keeping in mind that all the cytological features cannot be present in each case one should be careful not to miss PTC; on the other hand, care is also needed not to overdiagnose nuclear and/or pattern atypia in benign entities as PTC. 4 The two categories of the Bethesda System, "AUS/FLUS" and "suspicious for malignancy", are present for these equivocal findings and the degree of atypia determines the appropriate choice in reporting. immunohistochemistry are needed. 4 When amyloid is detected in thyroid FNA biopsies, MTC should be carefully searched for and excluded both by morphology and immunocytochemistry. 4, 50 The presence of amyloid can be a sign of primary or secondary amyloidosis (amyloid goitre) or can also accompany plasmacytomas and MALT lymphomas 4, 51 . Due to its resemblance to dense colloid, recognizing amyloid on cytology slides may be difficult. Both amyloid and colloid are seen as metachromatic in Diff-Quick and blue-greenpink-orange in PAP stains; amyloid looks more solid and hyaline-like than colloid. 4 The presence of amyloid may cause secondary inflammation, reactive changes and a giant cell reaction leading to an atypical/ suspicious diagnosis.
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Metastatic tumours
Discussing the pitfalls in thyroid cytology, metastatic malignancies always should be kept in mind. It is always a possibility in the presence of a thyroid nodule, especially in patients with known malignancy in other organs. Any cytomorphology picture, which is not typical for common primary thyroid tumours should alert us to this possibility 4 . Metastasis from adjacent anatomical regions to the thyroid (pharynx, larynx, oesophagus, mediastinum, and regional lymph nodes) and distant ones sites are the most common.Lung, breast, skin (especially melanoma), colon, and kidney should be included in the differential diagnosis, particularly for some PTC and MTC variants and rarer tumours of thyroid 2, 4 . However, distinguishing these entities by cytomorphology alone is nearly impossible as clinical findings and immunohistochemistry are needed. Immunocytochemistry can be applied in two steps.
First, TTF-1, TTF-2, PAX8 or TG should be performed to show a primary thyroid origin of the tumour. After this step, if required further organ-specific markers can be performed in the light of the clinical information to detect the primary origin of the tumour 2,4 .
Molecular tests and usefulness in false positive causes of thyroid FNA
Besides, cytomorphological, radiological, and clinical findings, molecular tests have a place in patient management to overcome the inherent limitations of thyroid cytology.
Molecular studies using cytological materials have gained increasing importance in recent years to decrease false positive rates and prevent unnecessary surgery 52 . According to the National Comprehensive Cancer Network guidelines, to gain a place in patient management for a molecular test the negative predictive value (NPV) should be >95% as a rule out test, whereas the positive predictive value (PPV) should be 95% as a rule in test to enable operations such as total thyroidectomy 53 . Currently some rule in and rule out molecular tests are already in routine use especially in the USA in patient management 53, 54 BRAF v 600E mutation: BRAF V600E mutation is known to be >99% specific for diagnosis of thyroid cancer (particularly for PTC), therefore mutational positivity of BRAF V600E is meaningful when cytomorphological findings indicate an indeterminate cytology result.
BRAF V600E testing is also useful in NIFTP diagnosis, since these tumours are follicular derived RAS-driven thyroid lesions and almost never show BRAF V600E mutations if strict morphological criteria for NIFTP are applied. When the strict diagnostic criteria of NIFTP are applied, the presence of a BRAF V600E mutation should therefore exclude a NIFTP tumour in FNA aspirates associated with the subtle nuclear changes of PTC with a very high degree of certainty 58 .
Medicolegal Implications
The expectation of patients and clinicians is that thyroid FNA will work as an effective diagnostic test, but given its limitations, it is inevitable that false was 94% (n=51) and for suspicious for malignancy TBSRTC category V, 37% (n=38) 61 .
Hence in this major study 6% of cases that were diagnosed as TBSRTC category VI (equivalent to Thy 5 in the UK) by local cytopathologists were downgraded on central cytopathology review. Since the risk of malignancy for TBSRTC category VI is less than 100%, patients need to be aware of the risk of malignancy and also the false negative risk in this category and a disclaimer about the risk of malignancy of each category can be presented in the cytology reports to inform both patients and their surgeons.
Conclusions
The main role of thyroid FNAC is the triage of patients who actually require surgery, thus reducing the number of unnecessary thyroidectomies and possible complications. 62 Ultrasound image features must be taken into account to plan appropriate patient management in a multidisciplinary approach to patient management. A cytology result with suspicious or malignant findings in the presence of a nodule with benign ultrasound features should be carefully studied to avoid a false positive diagnosis. As a cytological diagnosis of malignancy may require aggressive surgical treatment, including total thyroidectomy with possible central neck dissection, the correct FNA diagnosis is important to guide proper management of patients and to avoid overtreatment. In some cases if there is still uncertainty cell block immunohistochemistry of the current specimen or of a repeat thyroid FNAC and/or core biopsy will allow confirmation of the presence of malignancy and also the exact nature of the malignancy (e.g. medullary carcinoma or poorly differentiated carcinoma) . Molecular testing including for BRAF V600E mutation may also be helpful. All centres should audit their own practice of both thyroid cytology and histology to identify the risk of malignancy for all subcategories of thyroid FNAC, whether using TBSRTC, UK RCPath Thy or another internationally recongised terminology system bearing also in mind that the histopathological diagnosis may also be subject to significant interobserver variation 62. It is important to note that an accurate diagnosis by FNA crucially depends on the sample being representative and adequate in cellularity, appropriately processed, and stained, in order to provide high-quality 
